{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-097964","form_type":"8-K/A","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.940109+00:00","generated_at":"2026-06-17T03:39:45.507237+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bioventus finalizes employment terms for Interim CEO Anthony Bihl with $751K base salary","bullets":["Base salary of $751,000 per year; target annual bonus of 100% of base salary.","Equity awards: options for 198,000 shares and RSUs for 76,000 shares, both vesting fully on first anniversary.","Change-in-control severance: 18 months base salary, 150% target bonus, 18 months COBRA, plus full equity acceleration.","Restrictive covenants include perpetual confidentiality, non-disparagement, and 12-month non-compete (18 months after CIC).","Agreement effective April 5, 2023; signed on April 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-097964","json":"https://secwatch.observer/filing/0001193125-23-097964.json","markdown":"https://secwatch.observer/filing/0001193125-23-097964.md","text":"https://secwatch.observer/filing/0001193125-23-097964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523097964/0001193125-23-097964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523097964/d480678d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:39:45.507237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}